FINWIRES · TerminalLIVE
FINWIRES

China Water Industry Enters Rescheduling Deed With IFC

-- China Water Industry Group (HKG:1129) entered into a rescheduling deed with the International Finance Corporation, according to a Hong Kong bourse filing Friday.

Shares of the water supply company were down over 2% in Monday morning trade.

The rescheduling of payments to IFC was a condition for the company's proposed debt restructuring plan, which involves a bridge loan of HK$131.3 million and the issuance of convertible bonds.

The bridge loan will be used to partially settle amounts owed to the IFC, while the first tranche of convertible bonds to be issued will help settle the bridging loan itself.

Subsequent issues of the convertible bonds will be used to repay the remaining amounts owed to the IFC by March 31, 2027.

The IFC previously sought about 216.6 million yuan linked to a subsidiary of the company.

Related Articles

Asia

Eoptolink Technology 2025 Profit Jumps 236%; Shares Fall 8%

Eoptolink Technology (SHE:300502) posted 2025 attributable net profit of 9.53 billion yuan, up 236% from 2.84 billion yuan the previous year.Earnings per share rose to 9.57 yuan from 4.00 yuan, according to a Friday filing with the Shenzhen bourse.Revenue rose 187% year over year to 24.8 billion yuan from 8.64 billion yuan.Shares of the optical transceiver module manufacturer fell 8% in recent trade.

$SHE:300502
Asia

NZX Midday Sector Update: Consumer Durables Sector Soars, Technology Services Sector Struggles

The consumer durables shares gained the most on New Zealand's Exchange, rising almost 2% on Friday.Shares of KMD Brands (NZE:KMD, ASX:KMD) rose nearly 2% in recent trade.On the flip side, the technology services sector struggled, shedding past 3%.Shares of Gentrack Group (NZE:GTK, ASX:GTK) fell nearly 7% in recent trade.

$^NZ50$ASX:GTK$ASX:KMD$NZE:GTK$NZE:KMD
Asia

Daiichi Sankyo Raises Full-Year Forecasts on Forex Gains

Daiichi Sankyo (TYO:4568) raised its attributable profit forecast for the fiscal year ended March 31 to 2.5 billion yen from 1.7 billion yen previously, according to a Tokyo bourse filing on Friday.The pharmaceutical firm now expects earnings per share to be 103.26 yen, up from the earlier forecast of 70.16 yen, while the estimate for net sales has been slightly increased to 35.8 billion yen from 35.3 billion yen.The upward revision is primarily driven by a weaker Japanese yen compared with the company's initial assumption of 151 yen per U.S. dollar, resulting in significant foreign exchange gains on foreign currency-denominated assets and liabilities.For the full year, the company recorded total foreign exchange gains of 609 million yen as non-operating income, though this was partially offset by a 227 million yen allowance for doubtful accounts and 301 million yen in derivative valuation losses.Despite these offsets, the company expects ordinary profit to significantly exceed prior forecasts, while the year-end dividend forecast remains unchanged.

$TYO:4568